Abbott Laboratories
—- Market cap
- $177.58B
- Debt
- —
- Cash
- −$8.52B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $177.58B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
Decision snapshot: ABT stock price at premium vs MWA $101.95 current versus $73.00 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MWA's multiple
Implied fair value · at ABT's multiple
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
MUELLER WATER PRODUCTS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
ABT vs JNJ
Medtronic plc
ABT vs MDT
BECTON DICKINSON & CO
ABT vs BDX
Thermo Fisher Scientific Inc.
ABT vs TMO
DANAHER CORP /DE/
ABT vs DHR
BOSTON SCIENTIFIC CORP
ABT vs BSX
AMERICAN STATES WATER CO
ABT vs AWR
SMITH A O CORP
ABT vs AOS
Xylem Inc.
ABT vs XYL
American Water Works Company, Inc.
ABT vs AWK
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABT can reaccelerate growth and sustain premium margins while improving capital efficiency, then hold or add selectively because the current valuation already prices in a strong quality profile; otherwise, reduce exposure because ABT trades above MWA on P/E, P/S, EV/EBITDA, and EV/Revenue while the model-implied price suggests 24.6% downside.
ABT trades at a meaningful premium to MWA on earnings, sales, and enterprise value multiples, while the model-implied price points to 24.6% downside to $81.26 versus the current $107.81. ABT is only modestly above MWA implied range midpoint but remains below its historical upper band, suggesting valuation is rich relative to MWA comparison but not extreme versus its own history.
Supporting Metrics